Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Companies including GSK, Merck, Roche and Sanofi are pushing new approaches in cancer and inflammatory diseases.

The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years. More than 25 years after it was declared eliminated, measles has surged back. But drug ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

The Danish biotech sharpened its global vaccine ambitions by tapping Tarja Stenvall, a Big Pharma vet, to take the helm.

Patients in psychedelic trials often know if they’re taking the study drug or a placebo. But trial design changes could ...

The error points to a big question for pharma as AI gains autonomy and high-profile failures sharpen safety concerns: What ...

The program, part of Operation TrialBlazer, aims to speed early research and help the U.S. bring trials back from overseas.

The pharma and biotech industries are constantly in flux. Every year, pharma professionals converge on a number of large ...